Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
New Advances in the Treatment of Pediatric Solid Tumors
share announcement

New Advances in the Treatment of Pediatric Solid Tumors

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Pediatric Oncology".

Deadline for manuscript submissions: 20 November 2025 | Viewed by 722

Special Issue Editors

Prof. Dr. Myriam Weyl Ben-Arush

E-Mail Website
Guest Editor
Department of Pediatric Hematology and Oncology, Rambam Medical Center, Haifa, Israel
Interests: pediatric hematology-oncology; pediatric solid tumor; pediatric oncology; rhabdomyosarcoma; pediatric cancer care
Dr. Oz Mordechai

E-Mail Website
Guest Editor
Department of Pediatric Hematology and Oncology, Rambam Medical Center, Haifa, Israel
Interests: pediatric solid tumor; pediatric oncology

Special Issue Information

Dear Colleagues,

The treatment of pediatric solid tumors represents a critical and evolving area in oncology. Advances in molecular biology, precision medicine, surgical techniques, and multimodal therapies have significantly improved outcomes for children with solid tumors. Yet, challenges remain, particularly in addressing long-term toxicities, treatment resistance, and relapse.

This Special Issue of Cancers, titled "New Advances in the Treatment of Pediatric Solid Tumors", highlights recent innovations and breakthroughs in this field. Contributions are invited that explore cutting-edge therapies: genomic insights, novel biomarkers, immunotherapy applications, and the role of artificial intelligence to improve diagnostic and clinical strategies tailored to pediatric populations.

We hope this collection of work will serve as a valuable resource for clinicians, researchers, and policymakers dedicated to advancing care for children with solid tumors. We aim to inspire new approaches and improve outcomes for this vulnerable patient population by fostering interdisciplinary collaboration.

We hope this Special Issue will spark new ideas and foster meaningful collaborations that will lead to future advances in the care of pediatric solid tumors. We look forward to your valuable contributions.

Prof. Dr. Myriam Weyl Ben-Arush
Dr. Oz Mordechai
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pediatric oncology
  • solid tumors
  • precision medicine
  • immunotherapy
  • artificial intelligence
  • innovative therapies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

45 pages, 15819 KiB  
Review
The Molecular Basis of Pediatric Brain Tumors: A Review with Clinical Implications
by Elias Antoniades, Nikolaos Keffes, Stamatia Vorri, Vassilios Tsitouras, Nikolaos Gkantsinikoudis, Parmenion Tsitsopoulos and John Magras
Cancers 2025, 17(9), 1566; https://doi.org/10.3390/cancers17091566 - 4 May 2025
Viewed by 541
Abstract
Central nervous system (CNS) tumors are the most common solid malignancy in the pediatric population. These lesions are the result of the aberrant cell signaling step proteins, which normally regulate cell proliferation. Mitogen-activated protein kinase (MAPK) pathways and tyrosine kinase receptors are involved [...] Read more.
Central nervous system (CNS) tumors are the most common solid malignancy in the pediatric population. These lesions are the result of the aberrant cell signaling step proteins, which normally regulate cell proliferation. Mitogen-activated protein kinase (MAPK) pathways and tyrosine kinase receptors are involved in tumorigenesis of low-grade gliomas. High-grade gliomas may carry similar mutations, but loss of epigenetic control is the dominant molecular event; it can occur either due to histone mutations or inappropriate binding or unbinding of DNA on histones. Therefore, despite the absence of genetic alteration in the classic oncogenes or tumor suppressor genes, uncontrolled transcription results in tumorigenesis. Isocitric dehydrogenase (IDH) mutations do not predominate compared to their adult counterpart. Embryonic tumors include medulloblastomas, which bear mutations of transcription-regulating pathways, such as wingless-related integration sites or sonic hedgehog pathways. They may also relate to high expression of Myc family genes. Atypical teratoid rhabdoid tumors harbor alterations of molecules that contribute to ATP hydrolysis of chromatin. Embryonic tumors with multilayered rosettes are associated with microRNA mutations and impaired translation. Ependymomas exhibit great variability. As far as supratentorial lesions are concerned, the major events are mutations either of NFkB or Hippo pathways. Posterior fossa tumors are further divided into two types with different prognoses. Type A group is associated with mutations of DNA damage repair molecules. Lastly, germ cell tumors are a heterogeneous group. Among them, germinomas manifest KIT receptor mutations, a subgroup of the tyrosine kinase receptor family. Full article
(This article belongs to the Special Issue New Advances in the Treatment of Pediatric Solid Tumors)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop